SimVec-based HIV vaccine

**SimVec-based HIV vaccine** is an investigational therapeutic HIV vaccine developed by **GeneCure Biotechnologies** for treatment of **HIV infection**. It uses the company's patented **SimVec** lentiviral delivery platform, described as incorporating **vesicular stomatitis virus G protein** into the viral envelope to broaden cell entry, and is intended to induce rapid, strong **cell-mediated immune responses** against **HIV-infected cells** rather than prevent initial infection. According to the provided context, preclinical and early clinical testing, including the first-in-human proof-of-concept study **NCT01428596**, suggested the vaccine was well tolerated, boosted cellular immunity in people living with HIV, and was associated with durable control of viral load during a 12-week antiretroviral treatment interruption.

Other names

SimVec-based HIV vaccinetherapeutic HIV vaccine